SIETES :: 93072 citas

Resultados de la búsqueda por ARTRITIS REUMATOIDE REFINAR BÚSQUEDA

1.

Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]

2.

Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

3.

Anónimo. Drug prices continue to rise despite Trump’s rhetoric, analysis concludes. DIA Daily 2018:3. [Ref.ID 102715]

4.

Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]

5.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

6.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

7.

Anónimo. Arthritis drug prices rise 70 percent in three years despite increased competition. DIA Daily 0:1. [Ref.ID 102183]

8.

Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]

9.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

10.

Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernández-Díaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 2017;356:j895. [Ref.ID 101510]

11.

Anónimo. Inflectra - An infliximab biosimilar. Med Lett Drugs Ther 2017;59:23-5. [Ref.ID 101422]

12.

Alijotas-Reig J, Esteve-Valverde E. Embarazo y enfermedades autoinmunitarias. Med Clin (Barc) 2017;148:161-3. [Ref.ID 101400]

13.

Smolen JS, Burmester G-R, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 2016;388:2763-74. [Ref.ID 101029]

14.

Anónimo. J&J seeks FDA approval of guselkumab for psoriasis. DIA Daily 2016:3. [Ref.ID 100963]

15.

Anónimo. Experimental RA drug has mixed results in clinical trial against adalimumab. DIA Daily 2016:5. [Ref.ID 100937]

16.

Anónimo. Experimental treatment for RA showed mixed results against adalimumab in large trial, drugmakers says. DIA Daily 2016:4. [Ref.ID 100925]

17.

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38. [Ref.ID 100911]

18.

Anónimo. FDA declines to approve rheumatoid arthritis medication over manufacturing concerns. DIA Daily 2016:2. [Ref.ID 100867]

19.

Anónimo. Infliximab biosimilar dubbed noninferior in independent clinical trial by Norwegian government. DIA Daily 2016:6. [Ref.ID 100841]

20.

Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667-73. [Ref.ID 100766]